

FAST FACTS

URCC 16092: Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Cancer Patients Receiving Chemotherapy

Inclusion Criteria

Study participants must:

1. Be \geq 18 years of age
2. Have a diagnosis of cancer and are now receiving cytotoxic chemotherapy or have received cytotoxic chemotherapy within the last 6 months (i.e. are within a 6 month window of completion of chemotherapy).
3. Report cognitive difficulties or respond YES to the question: “Have you noticed any problems in your memory, attention, concentration, multi-tasking, or other cognitive functions?” NOTE: If a participant does not report cognitive difficulties or answers NO, they should be re-approached multiple times. Patients should be re-screened at all subsequent chemotherapy treatments and multiple times during the six months following completion of chemotherapy via phone and in person.
4. Be able to swallow medication.
5. Be able to read English.
6. Be able to give written informed consent.

Exclusion Criteria

Study participants must not:

1. Have a confirmed brain tumor or confirmed brain metastases.
2. Be taking regular daily doses of an NSAID. Note: Daily doses of 81 mg aspirin are permitted and higher doses of an NSAID on an ‘as needed’ basis are permitted.
3. Be diagnosed with dementia or severe neurodegenerative disease that would prohibit the ability to complete cognitive testing.
4. Have a contraindication to ibuprofen per physician or physician’s designee (e.g., allergy, worsening of ongoing medical problem due to NSAID, very low platelet count from chemotherapy, full-dose anti-coagulation/high risk of bleeding, as well as uncontrolled conditions such as hypertension, asthma, or peptic ulcer disease).
5. Have a hospitalization for treatment of a major psychiatric illness within the last five years.
6. Be pregnant.
7. Have a serum creatinine above 1.5 ULN. ULN is per institutional definition. If currently receiving chemotherapy, lab test must be collected within the 4 weeks prior to study enrollment. If not currently receiving chemotherapy, most recent labs tests may be used.
8. Be colorblind.
9. Have active substance abuse (e.g. alcohol, drugs) that would interfere with participation in

this study per self-report or medical record.

Schema

